Cargando…
The Anti-Non-Small Cell Lung Cancer Cell Activity by a mTOR Kinase Inhibitor PQR620
In non-small-cell lung carcinoma (NSCLC), aberrant activation of mammalian target of rapamycin (mTOR) contributes to tumorigenesis and cancer progression. PQR620 is a novel and highly-potent mTOR kinase inhibitor. We here tested its potential activity in NSCLC cells. In primary human NSCLC cells and...
Autores principales: | Zha, Jian-hua, Xia, Ying-chen, Ye, Chun-lin, Hu, Zhi, Zhang, Qin, Xiao, Han, Yu, Ben-tong, Xu, Wei-hua, Xu, Guo-qiu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222575/ https://www.ncbi.nlm.nih.gov/pubmed/34178653 http://dx.doi.org/10.3389/fonc.2021.669518 |
Ejemplares similares
-
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax
por: Tarantelli, Chiara, et al.
Publicado: (2019) -
Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines
por: Hsin, I-Lun, et al.
Publicado: (2021) -
mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms
por: Exner, Samantha, et al.
Publicado: (2021) -
ZDQ-0620, a Novel Phosphatidylinositol 3-Kinase Inhibitor, Inhibits Colorectal Carcinoma Cell Proliferation and Suppresses Angiogenesis by Attenuating PI3K/AKT/mTOR Pathway
por: Qin, Xiaochun, et al.
Publicado: (2022) -
The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside
por: Feng, Yimei, et al.
Publicado: (2021)